רשימת מקורות

  1. Bozarth AL, Bajaj N, Abdeljalil A. A review of venous thromboembolism prophylaxis for hospitalized medical patients. Hosp Pract (1995). 2013 Aug;41(3):60-9. 
  2. Raskob GE, Angchaisuksiri P, et.al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014;34:2363–2371.
  3. Mazzolai L, et.al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018 Dec 14;39(47):4208-4218.
  4. Flevas DA, Megaloikonomos PD, Dimopoulos L, Mitsiokapa E, Koulouvaris P, Mavrogenis AF. Thromboembolism prophylaxis in orthopaedics: an update. EFORT Open Rev. 2018;3(4):136–148. 
  5. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Gordon H. Guyatt, Elie A. Akl, Mark Crowther, Holger J. Schünemann, David D. Gutterman, Sandra Zelman Lewis. February 2012
  6. Wendelboe A.M., Mccumber M., Hylek E.M., Buller H., Weitz J. I. and Raskob G., For the ISTH steering committee for world thrombosis day. Global public awareness of venous thromboembolism. Journal of Thrombosis and Haemostasis, 2015; 13: 1365–1371. 
  7. A. Rabinovich A. and Kahn S .R. The postthrombotic syndrome: current evidence and future challenges. Journal of Thrombosis and Haemostasis, 2016; 15: 230–241
  8. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016 Jan;41(1):3-14.
  9. Brenner B, Hull R, Arya R, Beyer-Westendorf J, Douketis J, Elalamy I, Imberti D, Zhai Z. Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. Thromb J. 2019 Apr 15;17:6.
  10.  Freeman A., Pendleton R. and Rondina M., Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther. 2010 December ; 8(12): 1711–1721.
  11. Stone J., Hangge P., Albadawi H., Wallace A., Shamoun F., Knuttien M.G., Naidu S., Oklu R. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther. 2017 Dec;7(Suppl 3): S276-S284.
  12.  Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJM III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815.
  13. Lee, A.Y., et al. (2003) “Low-Molecular-Weight Heparin vs. Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer: Randomized Comparison of Low-Molecular-Weight Heparin vs. Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer.” New England Journal of Medicine 349:146-153.
  14. Office of the Surgeon General. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. 2008
  15. Kreutzer L., Minami C., Yang A., Preventing Venous Thromboembolism After Surgery. JAMA. 2016;315(19):2136. 
  16.  Emerging Strategies in the Prevention of Venous Thromboembolismin Hospitalized Medical Patients Alex c.Spyropoulos CHEST 2005
  17.  ENDORSE study:Venous thromboembolism risk and prophylaxis in the acute hospital care setting:a multinational cross-sectional study Alexander T. Cohen, Victor t. Tapson, Jean-Francois Bergman, Samuel Z Goldhaber, Ajay Kakkar,Bruno Deslands, Wei Huang, Maksim Zayaruzny, Leigh Emery, Frederick A Anderson Jr,   The Lancet 2008
  18.  Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14(4):341-346.
  19.  Samama MM, Cohen AT, Darmon J-Y, et al; Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793-800.
  20.  Colwell CW Jr, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999;81-A(7):932-940.
  21.  Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335(10):696-700.
  22.  ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997;84(8):1099-1103.
  23. ISTH Steering Committee for World Thrombosis Day. Thrombosis: A major contributor to global disease burden. Thrombosis Research Volume 134, Issue 5, November 2014, Pages 931-938
  24. Martinez C., Cohen A., Bamber L., Rietbrock S., Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer. Thromb Haemost. 2014 Aug;112(2):255-63.
  25. Huisman M.V., et al. Pulmonary embolism. Nature Reviews Disease Primers volume 4, Article number: 18028 (2018)
  26. Di Nisio M., et al., Deep vein thrombosis and pulmonary embolism. The Lancet. Volume 388, Issue 10063, p. 3060-3073, December 17, 2016. 
  27. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood. 2014 Mar 20;123(12):1794-801.
  28.  נתוני החברה הישראלית לקרישת הדם
  29. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27;2(22):3257-3291